Serbian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
glycogen storage disease/carbohydrate
Веза се чува у привремену меморију
Страна 1 од 166 резултати
Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor α (LXRα) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
GSD-1 (glycogen storage disease type 1) is caused by an inherited defect in glucose-6-phosphatase activity, resulting in a massive accumulation of hepatic glycogen content and an induction of de novo lipogenesis. The chlorogenic acid derivative S4048 is a pharmacological inhibitor of the glucose
Complex carbohydrates in the dietary management of patients with glycogenosis caused by glucose-6-phosphatase deficiency.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Carbohydrates with digestion characteristics between those of lente uncooked starches and rapidly digestible oligosaccharides were administered in a dose of 1.5 g/kg body weight to five patients with glycogenosis from glucose-6-phosphatase deficiency. Postprandial duration of normoglycemia and
Insulin-resistance in glycogen storage disease type Ia: linking carbohydrates and mitochondria?
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
BACKGROUND
Glycogen storage disease type I (GSDI) is an inborn error of carbohydrate metabolism caused by mutations of either the G6PC gene (GSDIa) or the SLC37A4 gene (GSDIb). GSDIa patients are at higher risk of developing insulin-resistance (IR). Mitochondrial dysfunction has been implicated in
[Carbohydrates in the treatment of glycogenoses].
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Glycogen storage diseases (GSD) include inborn errors in glycogen synthesis and degradation which, like most metabolic diseases, evades any therapeutical concept up to now. Nevertheless, in a subgroup of glycogenoses, characterized by functional absence of the key glycogenolytic enzyme
The dietary treatment of children with type I glycogen storage disease with slow release carbohydrate.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The effect of ingestion of uncooked cornstarch (2 g/kg body weight) in water, uncooked starch (1 g/kg) added to a meal, and glucose (2 g/kg) in water, was studied in eight patients with type IA glycogen storage disease (GSD) and one patient with type IB GSD. Blood glucose concentrations were
Impaired carbohydrate metabolism of polymorphonuclear leukocytes in glycogen storage disease Ib.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
This study measures hexose monophosphate (HMP) shunt activity, glycolytic rate, and glucose transport in PMN and lymphocytes of patients with glycogen storage disease (GSD) type Ib as compared with controls and with GSD Ia patients. HMP shunt activity and glycolysis were significantly lower in
[GLUCAGON. ITS ACTION ON CARBOHYDRATE METABOLISM. ITS CLINICAL APPLICATIONS IN THE DIAGNOSIS OF GLYCOREGULATION DISORDERS AND IN THE THERAPY OF HYPOGLYCEMIA AND GLYCOGENOSIS].
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The hyperlipemias in disorders of carbohydrate metabolism: serial lipoprotein studies in diabetic acidosis with xanthomatosis and in glycogen storage disease.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Glucose-6-phosphatase deficiency glycogen storage disease. Studies on the interrelationships of carbohydrate, lipid, and purine abnormalities.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
[Disorders of carbohydrate metabolism (glycogenoses): an overview].
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
The glycogenoses and other inherited disorders of carbohydrate metabolism.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Uric acid metabolism in therapy of glycogen storage disease type I.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Factors which may explain lower serum uric in a new therapy of patients with glycogen storage disease (GSD) type I have been studied. [1-14C]Glycine incorporation into urine uric acid was 0.68% of the injected dose during a 6-day period of frequent high carbohydrate feedings, 0.40% with the same
Unexplained hypoglycemia during continuous nocturnal gastric drip-feeding in a patient with glycogen storage disease type ia: is it a dumping-like syndrome?
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
A 5 years old boy affected with Glycogen Storage Disease type Ia (GSD-Ia) with previous optimal metabolic control developed severe erratic hypoglycemic episodes during continuous nocturnal gastric drip-feeding (CNGDF) administered by nasogastric tube. The episodes of hypoglycemia were not related to
Epilepsy and electrophysiological findings in polish twins with glycogenosis type IIIb.
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Glycogen storage diseases are rare genetic disorders, mostly autosomal recessively inherited. Abnormal accumulation is because of the lack of one of the enzymes involved in glycogen metabolism. Neurological manifestation of the diseases involves muscle weakness and hypoglycemia-induced seizures. In
[Home treatment of type I glycogenosis by continuous nocturnal gastric feeding].
Само регистровани корисници могу преводити чланке
Пријави се / Пријави се
Two children with type I glycogen-storage disease were treated at home with continuous nocturnal intragastric feeding, using a high glucose formula. The children were 6.5 years and 32 months old respectively when initiating treatment, and they have now been treated for 24 and 18 months. A high
Најкомплетнија база лековитог биља подржана науком
- Ради на 55 језика
- Биљни лекови потпомогнути науком
- Препознавање биљака по слици
- Интерактивна ГПС мапа - означите биље на локацији (ускоро)
- Читајте научне публикације повезане са вашом претрагом
- Претражите лековито биље по њиховим ефектима
- Организујте своја интересовања и будите у току са истраживањем вести, клиничким испитивањима и патентима
Упишите симптом или болест и прочитајте о биљкама које би могле да помогну, укуцајте неку биљку и погледајте болести и симптоме против којих се користи.
* Све информације се заснивају на објављеним научним истраживањима
